THYROID EYE DISEASE

This study tested a new drug called VRDN-003 in 87 people with thyroid eye disease (TED). The drug is given as a shot under the skin and targets a protein linked to the disease. The main goal was to check safety and how the drug moves through the body, not yet to measure how well…

This study looked at whether tocilizumab, a drug that calms the immune system, can help people with active moderate-to-severe thyroid eye disease that did not get better with steroids. Thirty-two adults received the drug every four weeks. Researchers measured improvements in eye …

This study tested an investigational drug called VRDN-001 in 143 people with thyroid eye disease who did not improve in earlier studies. The drug aims to reduce inflammation and eye bulging by blocking a specific receptor. Researchers measured how many participants had at least a…

This completed Phase 3 trial tested a drug called VRDN-001 in 231 people with thyroid eye disease (TED). The drug works by blocking a receptor involved in inflammation and swelling. The main goal was to check safety and tolerability, with secondary goals including measuring chang…

This Phase 3 trial tested whether batoclimab, an injected antibody, can reduce eye bulging (proptosis) in people with active, moderate-to-severe thyroid eye disease. 86 participants received weekly injections of batoclimab or a placebo for 24 weeks. The main goal was to see how m…

This study tested a new medicine called LASN01 in 41 adults with thyroid eye disease, a condition that causes eye bulging and discomfort. The goal was to see if LASN01 could safely reduce eye bulging compared to a placebo. Participants received either LASN01 or a dummy treatment …

This study looked at how safe and tolerable different lengths of treatment with teprotumumab are for adults with thyroid eye disease (TED). About 313 participants received the drug for varying durations to see if shorter treatment works as well and reduces side effects. The goal …

This Phase 2 trial tested whether injections of aflibercept, a drug that blocks abnormal blood vessel growth, are safe for people with active thyroid eye disease. Eleven adults received three injections over a month, with or without hyaluronidase to help spread the drug. The main…

This Phase 3 trial tested a drug called batoclimab in 114 adults with active, moderate-to-severe thyroid eye disease (TED). Participants received weekly injections of batoclimab or a placebo for 24 weeks. The main goal was to see if the drug could reduce eye bulging (proptosis) b…

This Phase 3 trial tested an investigational drug called veligrotug (VRDN-001) in 188 people with chronic thyroid eye disease. The drug is an antibody that blocks a protein involved in the disease. The main goal was to see if it could reduce eye bulging (proptosis) compared to a …

This Phase II study tested a new biologic drug called IBI311 in 38 people with thyroid eye disease, a condition that causes eye bulging and discomfort. Participants received different doses of the drug to see if it could safely reduce eye protrusion. The trial is completed, and r…

This completed study looked at how well teprotumumab (TEPEZZA) works in real-world use for 5 Chinese patients with thyroid eye disease. The main goal was to see how many patients had a reduction in eye bulging (proptosis) after their last IV infusion. The study also collected bas…